TNSN97087A1 - 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant - Google Patents
4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenantInfo
- Publication number
- TNSN97087A1 TNSN97087A1 TNTNSN97087A TNSN97087A TNSN97087A1 TN SN97087 A1 TNSN97087 A1 TN SN97087A1 TN TNSN97087 A TNTNSN97087 A TN TNSN97087A TN SN97087 A TNSN97087 A TN SN97087A TN SN97087 A1 TNSN97087 A1 TN SN97087A1
- Authority
- TN
- Tunisia
- Prior art keywords
- preparation
- pharmaceutical compositions
- compositions containing
- quinazolinones
- disubstituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Paints Or Removers (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSES DE FORMILE I :DANS LAQUELLE R1, R2 ET R3 REPRESENTENT DIVERS RADICAUX ORGANIQUES, ET LEURS SELS PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT DES PROCEDES POUR LEUR PREPARATION ET DES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT. APPLICATION : UTILISATION DANS LE TRAITEMENT DE MALADIE NEURO- DEGENERATIVES ET D'AFFECTIONS LIEES A UN TRAUMATISME DU SYSTEME NERVEUX CENTRAL.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1773896P | 1996-05-15 | 1996-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN97087A1 true TNSN97087A1 (fr) | 2005-03-15 |
Family
ID=21784266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN97087A TNSN97087A1 (fr) | 1996-05-15 | 1997-05-14 | 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant |
Country Status (39)
Country | Link |
---|---|
US (1) | US6303615B1 (fr) |
EP (1) | EP0901487B9 (fr) |
JP (1) | JP3241388B2 (fr) |
KR (1) | KR100375155B1 (fr) |
CN (2) | CN1103772C (fr) |
AP (1) | AP1148A (fr) |
AR (1) | AR007118A1 (fr) |
AT (1) | ATE242232T1 (fr) |
AU (1) | AU730503B2 (fr) |
BG (1) | BG102999A (fr) |
BR (1) | BR9709085A (fr) |
CA (1) | CA2252907C (fr) |
CZ (1) | CZ295565B6 (fr) |
DE (1) | DE69722613T2 (fr) |
DK (1) | DK0901487T3 (fr) |
DZ (1) | DZ2237A1 (fr) |
EA (1) | EA002905B1 (fr) |
ES (1) | ES2198546T3 (fr) |
GT (1) | GT199700049A (fr) |
HK (1) | HK1019607A1 (fr) |
HN (1) | HN1997000052A (fr) |
HR (1) | HRP970261B1 (fr) |
HU (1) | HUP9902148A3 (fr) |
ID (1) | ID17149A (fr) |
IL (1) | IL126589A (fr) |
IS (1) | IS4881A (fr) |
MA (1) | MA26430A1 (fr) |
NO (1) | NO985293L (fr) |
OA (1) | OA10918A (fr) |
PL (1) | PL330042A1 (fr) |
PT (1) | PT901487E (fr) |
SI (1) | SI0901487T1 (fr) |
SK (1) | SK284108B6 (fr) |
TN (1) | TNSN97087A1 (fr) |
TR (1) | TR199802296T2 (fr) |
TW (1) | TW539675B (fr) |
WO (1) | WO1997043276A1 (fr) |
YU (1) | YU19197A (fr) |
ZA (1) | ZA974156B (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6380204B1 (en) * | 1997-02-28 | 2002-04-30 | Pfizer Inc | Atropisomers of 3-heteroaryl-4(3H)-quinazolinones for the treatment of neurodegenerative and CNS-trauma related conditions |
HUP0000914A3 (en) * | 1997-02-28 | 2001-09-28 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and pharmaceutical compositions containing them |
US6060479A (en) * | 1997-06-09 | 2000-05-09 | Pfizer Inc | Quinazoline-4-one AMPA antagonists |
EP0900567A3 (fr) * | 1997-09-05 | 2001-05-02 | Pfizer Products Inc. | Quinazoline-4-ones antagonistes d'AMPA pour le traitement des dyscinésies associées à la thérapie aux agonistes de la dopamine |
IL125950A0 (en) * | 1997-09-05 | 1999-04-11 | Pfizer Prod Inc | Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy |
JPH11279158A (ja) * | 1998-02-09 | 1999-10-12 | Pfizer Prod Inc | キナゾリン―4―オン誘導体の製造方法 |
EP1153922B1 (fr) * | 1999-02-15 | 2006-04-26 | Eisai Co., Ltd. | Derives d'heterodiazinone |
US6890930B1 (en) * | 1999-09-28 | 2005-05-10 | 3-Dimensional Pharmaceuticals, Inc. | Quinazolinones |
US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
ES2320973T3 (es) | 2000-06-12 | 2009-06-01 | EISAI R&D MANAGEMENT CO., LTD. | Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos. |
US7053216B2 (en) | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
EP1537089A4 (fr) * | 2002-07-23 | 2008-04-16 | Cytokinetics Inc | Composes, compositions et procedes |
RS55551B1 (sr) | 2004-05-13 | 2017-05-31 | Icos Corp | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta |
MY148809A (en) | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
WO2007056124A2 (fr) * | 2005-11-04 | 2007-05-18 | Hydra Biosciences, Inc. | Composés destinés à moduler la fonction de trpv3 |
KR101129868B1 (ko) | 2006-10-04 | 2012-04-12 | 화이자 프로덕츠 인코포레이티드 | 칼슘 수용체 길항제로서의 피리도[4,3-d]피리미딘-4(3H)-온 유도체 |
WO2008140750A1 (fr) * | 2007-05-10 | 2008-11-20 | Hydra Biosciences Inc. | Composés modulant la fonction du trp v3 |
MX347987B (es) * | 2007-09-26 | 2017-05-22 | Celgene Corp * | Derivados de quinazolinona 6-,7-, u 8-sustituidos y composiciones que los comprenden y metodos para usar los mismos. |
PL2239257T3 (pl) | 2008-01-30 | 2012-10-31 | Shin Poong Pharmaceutical Co Ltd | Nowe pochodne chinazolino-2,4-dionu oraz zawierające je farmaceutyczne kompozycje do profilaktyki i leczenia chorób nerwów czaszkowych |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
US20100202963A1 (en) | 2008-11-13 | 2010-08-12 | Gallatin W Michael | Therapies for hematologic malignancies |
AU2010229968A1 (en) | 2009-03-24 | 2011-10-13 | Gilead Calistoga Llc | Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use |
ES2548253T3 (es) | 2009-04-20 | 2015-10-15 | Gilead Calistoga Llc | Métodos para el tratamiento de tumores sólidos |
BR112012001325A2 (pt) | 2009-07-21 | 2017-05-02 | Gilead Calistoga Llc | tratamento de distúrbios do fígado com inibidaores de pi3k |
US9216177B2 (en) | 2011-02-28 | 2015-12-22 | Drexel University | Small molecular inhibitors of RAD51 recombinase and methods thereof |
MX2014010656A (es) | 2012-03-05 | 2015-03-03 | Gilead Calistoga Llc | Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluo ro-3-fenilquinazolin-4(3h)-ona. |
EP3083623A1 (fr) | 2013-12-20 | 2016-10-26 | Gilead Calistoga LLC | Formes polymorphes d'un sel chlorhydrate de la (s)-2-(9h-purine-6-ylamino)propyl)-5-fluoro-3-phénylquinazolin-4(3h)-one |
AU2014364410B2 (en) | 2013-12-20 | 2017-11-16 | Gilead Calistoga Llc | Process methods for phosphatidylinositol 3-kinase inhibitors |
NZ726360A (en) | 2014-06-13 | 2018-04-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
KR20210107644A (ko) | 2018-12-14 | 2021-09-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 1,2-디하이드로피리딘 화합물의 수성 기반 약학적 제형 |
JP2023512664A (ja) | 2020-01-29 | 2023-03-28 | カマリ ファーマ リミテッド | 皮膚障害の治療に使用するための化合物及び組成物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1195321B (de) * | 1962-03-16 | 1965-06-24 | Troponwerke Dinklage & Co | Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten |
DE1670416A1 (de) * | 1966-12-30 | 1971-02-11 | Chem Fab Von Heyden Gmbh Muenc | Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten |
US3748325A (en) | 1970-04-06 | 1973-07-24 | Karamchand Premchand Private | Process for the preparation of quinazolinone derivatives |
AU543928B2 (en) * | 1981-01-16 | 1985-05-09 | Masayuki Ishikawa | 4(311)-quinazolinone derivatives |
GB9022785D0 (en) | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
WO1992013535A1 (fr) * | 1991-02-06 | 1992-08-20 | Research Corporation Technologies, Inc. | Quinazolones substituees a activite anticonvulsivante |
US5284957A (en) | 1992-09-03 | 1994-02-08 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
ATE148120T1 (de) | 1993-05-06 | 1997-02-15 | Novo Nordisk As | (1,2,4-triazolo(4,3-a>chinoxalinverbindungen deren herstellung und verwendung |
GB9400680D0 (en) * | 1994-01-14 | 1994-03-09 | Sandoz Ltd | Improvements in or relating to organic compounds |
HUP0000914A3 (en) | 1997-02-28 | 2001-09-28 | Pfizer Prod Inc | Atropisomers of 3-aryl-4(3h)-quinazolinones and pharmaceutical compositions containing them |
-
1997
- 1997-02-17 PT PT97901749T patent/PT901487E/pt unknown
- 1997-02-17 TR TR1998/02296T patent/TR199802296T2/xx unknown
- 1997-02-17 CZ CZ19983526A patent/CZ295565B6/cs not_active IP Right Cessation
- 1997-02-17 EA EA199800923A patent/EA002905B1/ru not_active IP Right Cessation
- 1997-02-17 ES ES97901749T patent/ES2198546T3/es not_active Expired - Lifetime
- 1997-02-17 EP EP97901749A patent/EP0901487B9/fr not_active Expired - Lifetime
- 1997-02-17 AU AU15549/97A patent/AU730503B2/en not_active Ceased
- 1997-02-17 DK DK97901749T patent/DK0901487T3/da active
- 1997-02-17 SK SK1520-98A patent/SK284108B6/sk unknown
- 1997-02-17 CA CA002252907A patent/CA2252907C/fr not_active Expired - Fee Related
- 1997-02-17 US US09/180,732 patent/US6303615B1/en not_active Expired - Fee Related
- 1997-02-17 AT AT97901749T patent/ATE242232T1/de not_active IP Right Cessation
- 1997-02-17 BR BR9709085A patent/BR9709085A/pt not_active Application Discontinuation
- 1997-02-17 CN CN97194654A patent/CN1103772C/zh not_active Expired - Fee Related
- 1997-02-17 WO PCT/IB1997/000134 patent/WO1997043276A1/fr active IP Right Grant
- 1997-02-17 PL PL97330042A patent/PL330042A1/xx unknown
- 1997-02-17 HU HU9902148A patent/HUP9902148A3/hu unknown
- 1997-02-17 JP JP54068297A patent/JP3241388B2/ja not_active Expired - Fee Related
- 1997-02-17 DE DE69722613T patent/DE69722613T2/de not_active Expired - Fee Related
- 1997-02-17 SI SI9730555T patent/SI0901487T1/xx unknown
- 1997-02-17 KR KR10-1998-0709205A patent/KR100375155B1/ko not_active IP Right Cessation
- 1997-04-08 TW TW086104460A patent/TW539675B/zh active
- 1997-04-21 HN HN1997000052A patent/HN1997000052A/es unknown
- 1997-04-29 GT GT199700049A patent/GT199700049A/es unknown
- 1997-05-13 AR ARP970102001A patent/AR007118A1/es not_active Application Discontinuation
- 1997-05-14 TN TNTNSN97087A patent/TNSN97087A1/fr unknown
- 1997-05-14 DZ DZ970085A patent/DZ2237A1/fr active
- 1997-05-14 ID IDP971603A patent/ID17149A/id unknown
- 1997-05-14 ZA ZA974156A patent/ZA974156B/xx unknown
- 1997-05-14 YU YU19197A patent/YU19197A/sh unknown
- 1997-05-14 MA MA24613A patent/MA26430A1/fr unknown
- 1997-05-15 AP APAP/P/1997/001003A patent/AP1148A/en active
- 1997-05-15 HR HR970261A patent/HRP970261B1/xx not_active IP Right Cessation
- 1997-12-17 IL IL12658997A patent/IL126589A/xx not_active IP Right Cessation
-
1998
- 1998-10-27 IS IS4881A patent/IS4881A/is unknown
- 1998-11-06 OA OA9800216A patent/OA10918A/en unknown
- 1998-11-13 NO NO985293A patent/NO985293L/no unknown
- 1998-12-08 BG BG102999A patent/BG102999A/xx active Pending
-
1999
- 1999-10-27 HK HK99104806A patent/HK1019607A1/xx not_active IP Right Cessation
-
2002
- 2002-09-05 CN CN02131946A patent/CN1420114A/zh active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN97087A1 (fr) | 4(3h)-quinazolinones 2,3-disubstituees nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98035A1 (fr) | Atropisomeres de 3-aryl-4(3h)-quinazolinones, procede pour leur preparation et compositions les contenant | |
TNSN96172A1 (fr) | Composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97055A1 (fr) | Derives de 6-phenylpyridyl -2- amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN99236A1 (fr) | Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN00104A1 (fr) | Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98083A1 (fr) | Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
MA26718A1 (fr) | Derives de quinoleine-2-one a substituant heteroaryle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99169A1 (fr) | Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97110A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98237A1 (fr) | Composes azapolycycliques a noyau aryle condense, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99156A1 (fr) | Derives d'acide hydroxypipecolate-hydroxamique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98154A1 (fr) | Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant | |
TNSN98150A1 (fr) | Derives d'acides aryloxyarylsulfonylaminohydroxamiques ; procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99039A1 (fr) | Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN96161A1 (fr) | Derives de la quinoleine et de quinazoline nouveaux procede pour leur preparation et formulations pharmaceutiques les contenant. | |
TNSN00065A1 (fr) | Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant. | |
TNSN99162A1 (fr) | Derives de quinoleine-2-one a substituant alcynyle nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99110A1 (fr) | Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN97078A1 (fr) | Derives d'indole nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant | |
TNSN99031A1 (fr) | Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98194A1 (fr) | Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant | |
TNSN98024A1 (fr) | 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
TNSN97044A1 (fr) | Derives de quinoxalinedone, procedes et intermediaires pour leur preparation, et compositions pharmaceutiques les contenant. |